Yale Cancer Center

The Society for Immunotherapy of Cancer announced the inaugural class of Fellows of the Academy of Immuno-Oncology.

Barbara Burtness, MD, understands that — in the medical profession — a culture of inclusion and diversity doesn’t just happen. It must be learned.

Nivolumab plus rucaparib demonstrated activity among men with chemotherapy-naive metastatic castration-resistant prostate cancer, according to results of cohort A2 of the CheckMate 9KD trial presented during the virtual ESMO Congress 2021.

Data suggest that practicing mindfulness — the quality or state of being conscious or aware — may decrease levels of burnout, enhance satisfaction with life and lead to better patient care among oncologists.

Lakshmanan Krishnamurti, MD, has been appointed chief of pediatric hematology, oncology and bone marrow transplant at Yale New Haven Children’s Hospital.

Nomenclature for low-grade prostate cancer affected initial perception of the disease among online survey participants presented with a hypothetical clinical scenario, according to research published in Cancer.

FDA’s Oncologic Drugs Advisory Committee today voted 13 to 4 to recommend deferral of a regulatory decision on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal.

In this video, Roy Herbst, MD, PhD, spoke with Healio about the practice changing IMpower010 trial presented at the virtual ASCO Annual Meeting.

Roy Herbst, MD, PhD, discussed updated toxicity data from the Lung-MAP non-matched sub-study S1800A presented at the virtual ASCO Annual Meeting.

Thirty-four physicians have received Fellow of the American Society of Clinical Oncology distinction.